Research programme: cancer therapeutics - NuCana

Drug Profile

Research programme: cancer therapeutics - NuCana

Alternative Names: Azacitidine ProTide - NuCana; Capecitabine ProTide - NuCana; Cladiribine ProTide - NuCana; Decitabine ProTide - NuCana; Fludarabine ProTide - NuCana; NUC 4545; NUC 5435; NUC 6285; NUC 7000; NUC 7738; NUC 8000; NUC 9324

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiff University
  • Developer NuCana
  • Class Nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (IV)
  • 21 Mar 2018 NuCana plans a clinical trial for NUC 7738 for Solid tumours in 2018
  • 23 Mar 2016 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top